Objective: the experiment will apply Liuweidihuang decoction to patients with chronic glomerulonephritis. At the same time, we will also compare the patient's condition management results under the treatment of we...Objective: the experiment will apply Liuweidihuang decoction to patients with chronic glomerulonephritis. At the same time, we will also compare the patient's condition management results under the treatment of western medicine, and further analyze the therapeutic efficacy of patients under the two schemes of traditional Chinese and western medicine. Methods: 40 cases of patients with chronic glomerulonephritis treated in our hospital from January 2018 to February 2020 were selected as the objects of this study. The control group was treated with western medicine, while the observation group was treated with Liuweidihuang decoction. The efficacy was compared. Results: in terms of treatment, Scr and BUN levels in the observation group were (117.65±28.13) g/L and (6.55±2.04) umol/L, respectively, which were better than those in the control group, with statistical significance (P < 0.05). At the same time, the therapeutic effect was compared, and the observation group was better. The two groups were 95.0% and 80.0% respectively. The difference was statistically significant. Finally, the TCM symptoms of the patients were compared, which mainly included fatigue, psoas acid softness and edema. The scores were all better in the observation group. Conclusion: Liuweidihuang decoction in the treatment of chronic glomerulonephritis can improve the levels of Scr and BUN, enhance the therapeutic effect, which can alleviate the development of the disease, properly control and solve the clinical symptoms, and it is recommended to promote its application.展开更多
Objective: to observe the clinical effect of intravenous thrombolysis with alteplase combined with Shuxuening injection on ischemic stroke. Methods: selected subjects: 90 patients with acute ischemic stroke in the eme...Objective: to observe the clinical effect of intravenous thrombolysis with alteplase combined with Shuxuening injection on ischemic stroke. Methods: selected subjects: 90 patients with acute ischemic stroke in the emergency department of our hospital were selected from March 2021 to August 2022. They were grouped according to the computer parity distribution method, the control group database (45 patients data), and the observation group database (43 patients data), and Shuxuening injection combined with alteplase therapy. To observe the effects of different therapies on the clinical effect, neurological function score, inflammatory value, neurotransmitter and coagulation value of patients. Results: compared with the parameter difference between groups, there was no significant difference in data before treatment (P > 0.05). After treatment, the results of data comparison were significant, the clinical treatment effect of the patients in the observation group was significantly improved, the inflammatory values and neurological function scores were significantly decreased, and the neurotransmitters and coagulation values were significantly improved, P<0.05. Conclusion: the combined therapy of intravenous thrombolysis with alteplase and Shuxuening injection for patients with acute ischemic stroke has a significant clinical effect, which can effectively change the patients condition and improve the inflammatory response and neurological function.展开更多
文摘Objective: the experiment will apply Liuweidihuang decoction to patients with chronic glomerulonephritis. At the same time, we will also compare the patient's condition management results under the treatment of western medicine, and further analyze the therapeutic efficacy of patients under the two schemes of traditional Chinese and western medicine. Methods: 40 cases of patients with chronic glomerulonephritis treated in our hospital from January 2018 to February 2020 were selected as the objects of this study. The control group was treated with western medicine, while the observation group was treated with Liuweidihuang decoction. The efficacy was compared. Results: in terms of treatment, Scr and BUN levels in the observation group were (117.65±28.13) g/L and (6.55±2.04) umol/L, respectively, which were better than those in the control group, with statistical significance (P < 0.05). At the same time, the therapeutic effect was compared, and the observation group was better. The two groups were 95.0% and 80.0% respectively. The difference was statistically significant. Finally, the TCM symptoms of the patients were compared, which mainly included fatigue, psoas acid softness and edema. The scores were all better in the observation group. Conclusion: Liuweidihuang decoction in the treatment of chronic glomerulonephritis can improve the levels of Scr and BUN, enhance the therapeutic effect, which can alleviate the development of the disease, properly control and solve the clinical symptoms, and it is recommended to promote its application.
文摘Objective: to observe the clinical effect of intravenous thrombolysis with alteplase combined with Shuxuening injection on ischemic stroke. Methods: selected subjects: 90 patients with acute ischemic stroke in the emergency department of our hospital were selected from March 2021 to August 2022. They were grouped according to the computer parity distribution method, the control group database (45 patients data), and the observation group database (43 patients data), and Shuxuening injection combined with alteplase therapy. To observe the effects of different therapies on the clinical effect, neurological function score, inflammatory value, neurotransmitter and coagulation value of patients. Results: compared with the parameter difference between groups, there was no significant difference in data before treatment (P > 0.05). After treatment, the results of data comparison were significant, the clinical treatment effect of the patients in the observation group was significantly improved, the inflammatory values and neurological function scores were significantly decreased, and the neurotransmitters and coagulation values were significantly improved, P<0.05. Conclusion: the combined therapy of intravenous thrombolysis with alteplase and Shuxuening injection for patients with acute ischemic stroke has a significant clinical effect, which can effectively change the patients condition and improve the inflammatory response and neurological function.
